Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
- Conditions
- Refractory Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory T-Cell Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Mantle Cell LymphomaRecurrent Mantle Cell LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarmustineDrug: CytarabineDrug: EtoposideOther: Laboratory Biomarker AnalysisDrug: MelphalanProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
- First Posted Date
- 2013-08-13
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01921387
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2013-08-12
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT01920737
- Locations
- 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Pure Erythroid Leukemia (M6b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 17
- Registration Number
- NCT01904643
- Locations
- 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- FLT3 Gene Mutation NegativeRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Chronic Myelomonocytic LeukemiaFLT3 Internal Tandem Duplication PositiveRefractory Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT01892371
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
- Conditions
- Acute Leukaemia
- Interventions
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 148
- Registration Number
- NCT01890746
- Locations
- 🇷🇺
Novartis Investigative Site, Tula, Russian Federation
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndromes, Myelogenous Leukemia, Acute
- Interventions
- First Posted Date
- 2013-06-19
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT01880437
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01876953
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With MaturationAdult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1Adult Acute Myelomonocytic LeukemiaAdult ErythroleukemiaAlkylating Agent-Related Acute Myeloid LeukemiaAdult Acute Megakaryoblastic LeukemiaAdult Acute Monoblastic LeukemiaAdult Acute Monocytic LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With Minimal Differentiation
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT01870596
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
- Conditions
- Lymphoblastic Leukemia, Acute, ChildhoodMyelogenous Leukemia, Acute, Childhood
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 15
- Registration Number
- NCT01861002
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇨🇦Sainte-Justine University Hospital Center, Montreal, Quebec, Canada
🇺🇸Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Erythroleukemia (M6a)Blastic Phase Chronic Myelogenous LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 2
- Registration Number
- NCT01849276
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.